|
|
|
||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Nu Skin Enterprises’ press release dated February 10, 2021, regarding financial results for the three-month and annual periods ended December 31, 2020.
|
|
Nu Skin Enterprises’ press release dated February 10, 2021, regarding CEO transition.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
NU SKIN ENTERPRISES, INC.
|
||
(Registrant)
|
||
/s/ Mark H. Lawrence
|
||
Mark H. Lawrence
|
||
Chief Financial Officer
|
||
Date: February 11, 2021
|
Revenue:
|
$748.2 million; +28%
● +4% fx impact
|
Earnings Per Share (EPS):
|
$1.40; +94%
|
Sales Leaders:
|
70,435; +29%
|
Customers:
|
1,557,302; +34%
|
Revenue:
|
$2.58 billion; +7%
● Less than (1%) fx impact
|
Earnings Per Share (EPS):
|
$3.63; +17%
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 2
|
Revenue:
|
$748.2 million compared to $583.4 million
● +4% fx impact
|
Gross Margin:
|
74.0% compared to 75.9%
● Nu Skin business was 76.5% compared to 78.5%
● Impacted by increased freight charges and geographic
mix
|
Selling Expenses:
|
38.0% compared to 39.1%
● Nu Skin business was 40.3% compared to 41.3%
|
G&A Expenses:
|
24.1% compared to 27.4%
|
Operating Margin:
|
11.9% compared to 9.4%
|
Other Income / (Expense):
|
$2.7 million compared to ($1.1) million
|
Income Tax Rate:
|
19.6% compared to 25.1%
● Benefited by geographic mix
|
EPS:
|
$1.40 compared to $0.72
|
Dividend Payments:
|
$19.1 million
|
Stock Repurchases:
|
$17.0 million
● $325.8 million remaining in authorization
|
Q1 2021 Revenue:
|
● Approximately +3% fx impact
|
Q1 2021 EPS:
|
$0.65 to $0.75; +81 to 108%
|
2021 Revenue:
|
● Approximately +2 to 3% fx impact
|
2021 EPS:
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 3
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 4
|
● |
risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
|
● |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
● |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or
enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines,
or any other adverse actions or events;
|
● |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling
activities on a sustained basis;
|
● |
political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
|
● |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on
our business operations and results;
|
● |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
● |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
● |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and
increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
|
● |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling
a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
|
● |
unpredictable economic conditions and events globally, including trade policies and tariffs;
|
● |
the company’s future tax-planning initiatives; any prospective or retrospective increases in duties on the company’s products imported into the company’s markets
outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets; and
|
● |
continued competitive pressures in the company’s markets.
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 5
|
Three Months Ended
December 31,
|
Constant-
Currency
|
|||||||||||||||
2020
|
2019
|
Change
|
Change
|
|||||||||||||
Nu Skin
|
||||||||||||||||
Mainland China
|
$
|
172,442
|
$
|
154,731
|
11
|
%
|
5
|
%
|
||||||||
Americas/Pacific
|
157,984
|
86,146
|
83
|
%
|
86
|
%
|
||||||||||
South Korea
|
90,384
|
81,958
|
10
|
%
|
5
|
%
|
||||||||||
Southeast Asia
|
82,191
|
74,767
|
10
|
%
|
10
|
%
|
||||||||||
Japan
|
73,132
|
65,482
|
12
|
%
|
7
|
%
|
||||||||||
EMEA
|
82,656
|
46,205
|
79
|
%
|
68
|
%
|
||||||||||
Hong Kong/Taiwan
|
45,864
|
41,616
|
10
|
%
|
5
|
%
|
||||||||||
Other
|
(391
|
)
|
1,860
|
(121
|
)%
|
(121
|
)%
|
|||||||||
Total Nu Skin
|
704,262
|
552,765
|
27
|
%
|
23
|
%
|
||||||||||
Manufacturing
|
43,364
|
30,487
|
42
|
%
|
42
|
%
|
||||||||||
Grow Tech
|
567
|
107
|
430
|
%
|
430
|
%
|
||||||||||
Total
|
$
|
748,193
|
$
|
583,359
|
28
|
%
|
24
|
%
|
Year Ended
December 31,
|
Constant-
Currency
|
|||||||||||||||
2020
|
2019
|
Change
|
Change
|
|||||||||||||
Nu Skin
|
||||||||||||||||
Mainland China
|
$
|
625,538
|
$
|
722,526
|
(13
|
)%
|
(14
|
)%
|
||||||||
Americas/Pacific
|
511,941
|
349,078
|
47
|
%
|
53
|
%
|
||||||||||
South Korea
|
326,478
|
329,978
|
(1
|
)%
|
—
|
|||||||||||
Southeast Asia
|
302,708
|
301,620
|
—
|
1
|
%
|
|||||||||||
Japan
|
273,681
|
260,039
|
5
|
%
|
3
|
%
|
||||||||||
EMEA
|
230,246
|
167,165
|
38
|
%
|
35
|
%
|
||||||||||
Hong Kong/Taiwan
|
161,117
|
166,335
|
(3
|
)%
|
(6
|
)%
|
||||||||||
Other
|
(17
|
)
|
1,621
|
(101
|
)%
|
(101
|
)%
|
|||||||||
Total Nu Skin
|
2,431,692
|
2,298,362
|
6
|
%
|
6
|
%
|
||||||||||
Manufacturing
|
149,339
|
121,917
|
22
|
%
|
22
|
%
|
||||||||||
Grow Tech
|
903
|
137
|
559
|
%
|
559
|
%
|
||||||||||
Total
|
$
|
2,581,934
|
$
|
2,420,416
|
7
|
%
|
7
|
%
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 6
|
2020
|
2019
|
% Increase (Decrease)
|
||||||||||||||||||||||
Customers
|
Sales
Leaders
|
Customers
|
Sales
Leaders
|
Customers
|
Sales Leaders
|
|||||||||||||||||||
Mainland China
|
381,460
|
21,990
|
292,812
|
17,987
|
30
|
%
|
22
|
%
|
||||||||||||||||
Americas/Pacific
|
404,955
|
14,439
|
220,216
|
7,607
|
84
|
%
|
90
|
%
|
||||||||||||||||
South Korea
|
158,953
|
7,059
|
168,972
|
7,251
|
(6
|
)%
|
(3
|
)%
|
||||||||||||||||
Southeast Asia
|
154,355
|
8,903
|
136,349
|
7,480
|
13
|
%
|
19
|
%
|
||||||||||||||||
Japan
|
128,400
|
6,318
|
125,557
|
5,916
|
2
|
%
|
7
|
%
|
||||||||||||||||
EMEA
|
258,587
|
7,063
|
153,330
|
4,619
|
69
|
%
|
53
|
%
|
||||||||||||||||
Hong Kong/Taiwan
|
70,592
|
4,663
|
65,669
|
3,900
|
7
|
%
|
20
|
%
|
||||||||||||||||
Total
|
1,557,302
|
70,435
|
1,162,905
|
54,760
|
34
|
%
|
29
|
%
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 7
|
Three Months Ended
December 31,
|
Years Ended
December 31,
|
|||||||||||||||
2020
|
2019
|
2020
|
2019
|
|||||||||||||
Revenue
|
$
|
748,193
|
$
|
583,359
|
$
|
2,581,934
|
$
|
2,420,416
|
||||||||
Cost of sales
|
194,751
|
140,566
|
658,028
|
581,420
|
||||||||||||
Gross profit
|
553,442
|
442,793
|
1,923,906
|
1,838,996
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Selling expenses
|
284,129
|
228,127
|
1,019,494
|
955,600
|
||||||||||||
General and administrative expenses
|
180,616
|
159,987
|
646,848
|
615,970
|
||||||||||||
Total operating expenses
|
464,745
|
388,114
|
1,666,342
|
1,571,570
|
||||||||||||
Operating income
|
88,697
|
54,679
|
257,564
|
267,426
|
||||||||||||
Other income (expense), net
|
2,736
|
(1,101
|
)
|
(1,332
|
)
|
(12,254
|
)
|
|||||||||
Income before provision for income taxes
|
91,433
|
53,578
|
256,232
|
255,172
|
||||||||||||
Provision for income taxes
|
17,966
|
13,466
|
64,877
|
81,619
|
||||||||||||
Net income
|
$
|
73,467
|
$
|
40,112
|
$
|
191,355
|
$
|
173,553
|
||||||||
Net income per share:
|
||||||||||||||||
Basic
|
$
|
1.44
|
$
|
0.72
|
$
|
3.66
|
$
|
3.13
|
||||||||
Diluted
|
$
|
1.40
|
$
|
0.72
|
$
|
3.63
|
$
|
3.10
|
||||||||
Weighted-average common shares outstanding (000s):
|
||||||||||||||||
Basic
|
50,971
|
55,548
|
52,296
|
55,518
|
||||||||||||
Diluted
|
52,403
|
55,807
|
52,765
|
55,927
|
Nu Skin Enterprises Reports Fourth-quarter Revenue Growth
|
Page 8
|
December 31, 2020
|
December 31, 2019
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
402,683
|
$
|
335,630
|
||||
Current investments
|
21,216
|
8,413
|
||||||
Accounts receivable, net
|
63,370
|
50,378
|
||||||
Inventories, net
|
314,366
|
275,891
|
||||||
Prepaid expenses and other
|
101,563
|
69,854
|
||||||
Total current assets
|
903,198
|
740,166
|
||||||
Property and equipment, net
|
468,181
|
453,604
|
||||||
Operating lease right-of-use assets
|
155,104
|
144,326
|
||||||
Goodwill
|
202,979
|
196,573
|
||||||
Other intangible assets, net
|
89,532
|
80,321
|
||||||
Other assets
|
138,082
|
154,016
|
||||||
Total assets
|
$
|
1,957,076
|
$
|
1,769,006
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
66,174
|
$
|
38,979
|
||||
Accrued expenses
|
446,682
|
290,281
|
||||||
Current portion of long-term debt
|
30,000
|
27,500
|
||||||
Total current liabilities
|
542,856
|
356,760
|
||||||
Operating lease liabilities
|
112,275
|
105,701
|
||||||
Long-term debt
|
305,393
|
334,461
|
||||||
Other liabilities
|
102,281
|
96,795
|
||||||
Total liabilities
|
1,062,805
|
893,717
|
||||||
Stockholders’ equity:
|
||||||||
Class A common stock
|
91
|
91
|
||||||
Additional paid-in capital
|
579,801
|
557,544
|
||||||
Treasury stock, at cost
|
(1,461,593
|
)
|
(1,324,826
|
)
|
||||
Accumulated other comprehensive loss
|
(64,768
|
)
|
(85,292
|
)
|
||||
Retained earnings
|
1,840,740
|
1,727,772
|
||||||
Total stockholders' equity
|
894,271
|
875,289
|
||||||
Total liabilities and stockholders’ equity
|
$
|
1,957,076
|
$
|
1,769,006
|